Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our discovery efforts have resulted in four approved products and we have partnered with leading pharmaceutical companies to bring these important medicines to patients worldwide. We are committed to prudently reinvesting in our business to maximize the potential of our pipeline, all to deliver the next generation of Exelixis medicines and help cancer patients recover stronger and live longer.